Summit Therapeutics Inc Stock Ownership - Who owns Summit Therapeutics?

Insider buying vs selling

Have Summit Therapeutics Inc insiders been buying or selling?
Mahkam ZanganehChief Executive Officer2024-03-2720,000$3.71
Mahkam ZanganehChief Executive Officer2024-03-2726,000$3.72
Mahkam ZanganehChief Executive Officer2024-03-2734,321$3.72
Mahkam ZanganehChief Executive Officer2024-03-2630,000$3.75
Ankur DhingraChief Financial Officer2024-03-26100,000$3.75
Ankur DhingraChief Financial Officer2023-12-1319,700$2.17
Ankur DhingraChief Financial Officer2023-12-13700$2.15
Mahkam ZanganehChief Executive Officer2023-12-125,000$2.07
Mahkam ZanganehChief Executive Officer2023-12-11489,814$1.44
Mahkam ZanganehChief Executive Officer2023-12-11315,681$1.58

1 of 2

SMMT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SMMT insiders and whales buy or sell their stock.

SMMT Shareholders

What type of owners hold Summit Therapeutics Inc stock?
Robert W. Duggan78.69%552,354,161$4.38BInsider
Mahkam Zanganeh8.54%59,952,507$475.42MInsider
Yu Xia3.07%21,523,530$170.68MInsider
Maky Zanganeh2.12%14,915,775$118.28MInsider
Blackrock Inc1.40%9,823,341$77.90MInstitution
State Street Corp1.16%8,114,230$64.35MInstitution
Fmr LLC1.14%7,974,531$63.24MInstitution
Vanguard Group Inc1.04%7,269,243$57.65MInstitution
Geode Capital Management LLC0.45%3,152,390$25.00MInstitution
Manmeet Singh Soni0.42%2,976,190$23.60MInsider

1 of 3

SMMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SMMT7.07%92.92%Net BuyingNet Buying
CYTK88.55%11.45%Net SellingNet Selling
VKTX72.41%9.00%Net SellingNet Selling
NUVL70.18%29.82%Net SellingNet Selling
MDGL23.85%76.15%Net BuyingNet Selling

Summit Therapeutics Stock Ownership FAQ

Who owns Summit Therapeutics?

Summit Therapeutics (NASDAQ: SMMT) is owned by 7.07% institutional shareholders, 92.92% Summit Therapeutics insiders, and 0.02% retail investors. Robert W. Duggan is the largest individual Summit Therapeutics shareholder, owning 552.35M shares representing 78.69% of the company. Robert W. Duggan's Summit Therapeutics shares are currently valued at $4.42B.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.